Milestone Pharmaceuticals (MIST)
(Delayed Data from NSDQ)
$1.92 USD
-0.03 (-1.54%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.92 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MIST 1.92 -0.03(-1.54%)
Will MIST be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MIST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIST
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst
MIST: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright
Other News for MIST
Is MIST coiling for a breakout? NR7 shows up after advancing 0.52%
MIST forms Upper Bollinger Band Walk on September 17
MIST forms Death Cross on September 16
Is MIST signaling a buying opportunity? New Uptrend shows up after advancing 0.51%
Analysts Offer Insights on Healthcare Companies: Kala Pharmaceuticals (KALA) and Milestone Pharmaceuticals (MIST)